Hospital
Upmc Carlisle
Upmc Carlisle was paid $3.56M by Medicaid between Oct 2018 and Dec 2024, across 127 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoUPMC CARLISLE
CARLISLE, PA 17015
CARLISLE, PA 17015
33aNPI1689107328assigned 04/10/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.56M
24GClaims114,999
24DCodes billed127
24AFirst – last monthOct 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#72 of 154
Median peer was paid$2.82M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21 | $3K | |
| 2019 | 316 | $6K | |
| 2020 | 10,207 | $273K | |
| 2021 | 39,344 | $1.11M | |
| 2022 | 17,514 | $586K | |
| 2023 | 26,199 | $767K | |
| 2024incomplete | 21,398 | $809K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 12,457 | 11,981 | $1.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 7,700 | 7,462 | $557K |
| G0378 | Hospital observation service, per hour | 13% | 582 | 562 | $449K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.8% | 2,421 | 2,340 | $277K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 4,169 | 3,833 | $107K |
| 80053 | Comprehensive metabolic panel | 2.6% | 9,429 | 8,705 | $94K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 551 | 542 | $92K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.0% | 1,164 | 1,138 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 14,062 | 12,941 | $69K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 5,624 | 5,286 | $54K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 475 | 450 | $41K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 666 | 590 | $34K |
115 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,340 | $33K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 564 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 601 | $32K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,051 | $31K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,929 | $27K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 699 | $24K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,460 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 269 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,976 | $18K |
| 84484 | <1% | 1,943 | $17K | |
| 80061 | Lipid panel | <1% | 1,065 | $15K |
| 81001 | <1% | 4,807 | $12K | |
| 80050 | General health panel | <1% | 276 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 545 | $12K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 91 | $11K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,230 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,313 | $9K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 228 | $8K |
| 83690 | <1% | 1,788 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 364 | $7K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 79 | $7K |
| 84702 | <1% | 376 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 873 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 267 | $6K |
| 83880 | <1% | 258 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 41 | $6K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 269 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,507 | $6K |
| 85027 | <1% | 840 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 183 | $4K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 120 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 746 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 69 | $4K |
| 82728 | <1% | 343 | $4K | |
| 83735 | <1% | 788 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 646 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 176 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 120 | $3K |
| 71250 | <1% | 55 | $3K | |
| 84439 | <1% | 359 | $3K | |
| 93971 | <1% | 45 | $3K | |
| 83605 | <1% | 464 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 61 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 75 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 48 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 160 | $2K |
| 83540 | <1% | 277 | $2K | |
| 85610 | <1% | 746 | $2K | |
| 86803 | <1% | 99 | $2K | |
| 73610 | <1% | 100 | $2K | |
| 80076 | <1% | 232 | $2K | |
| 94729 | <1% | 71 | $2K | |
| 94726 | <1% | 71 | $2K | |
| 87186 | <1% | 236 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 75 | $2K |
| 84703 | <1% | 159 | $2K | |
| 73630 | <1% | 135 | $1K | |
| 83550 | <1% | 266 | $1K | |
| 82607 | <1% | 117 | $1K | |
| 86787 | <1% | 67 | $1K | |
| 87077 | <1% | 204 | $1K | |
| 80081 | <1% | 12 | $1K | |
| 86140 | <1% | 341 | $981.91 | |
| 12001 | <1% | 12 | $970.85 | |
| 82570 | <1% | 125 | $962.37 | |
| 76857 | <1% | 45 | $931.90 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 146 | $910.08 |
| 85730 | <1% | 210 | $866.21 | |
| 86900 | <1% | 214 | $808.88 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $796.25 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 16 | $777.07 |
| 86901 | <1% | 199 | $758.80 | |
| 87081 | <1% | 127 | $714.32 | |
| 83615 | <1% | 94 | $668.98 | |
| 85652 | <1% | 218 | $651.94 | |
| 94060 | <1% | 75 | $616.10 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 121 | $598.42 |
| 82565 | <1% | 92 | $589.23 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,112 | $583.10 |
| J3490 | Unclassified drugs | <1% | 718 | $566.29 |
| 76642 | <1% | 12 | $550.63 | |
| 83020 | <1% | 41 | $464.75 | |
| 84550 | <1% | 71 | $459.07 | |
| 82550 | <1% | 77 | $455.78 | |
| J2704 | Injection, propofol, 10 mg | <1% | 570 | $408.26 |
| 86850 | <1% | 55 | $387.80 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 27 | $378.43 |
| 87040 | <1% | 17 | $343.17 | |
| 85379 | <1% | 40 | $323.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,569 | $275.32 |
| 84156 | <1% | 59 | $257.94 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,776 | $226.52 |
| 87070 | <1% | 39 | $221.25 | |
| 86592 | <1% | 53 | $212.60 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 16 | $197.87 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 319 | $156.32 |
| 83655 | <1% | 12 | $138.90 | |
| 96376 | <1% | 57 | $134.40 | |
| 87205 | <1% | 28 | $113.91 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 395 | $100.93 |
| 84100 | <1% | 29 | $96.34 | |
| 84460 | <1% | 13 | $91.08 | |
| 81003 | <1% | 38 | $88.01 | |
| 81025 | <1% | 22 | $69.63 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 384 | $55.86 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 15 | $38.60 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 56 | $24.57 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 432 | $17.59 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 410 | $15.63 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,241 | $15.09 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 51 | $7.88 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 29 | $7.76 |
| 36415 | Collection of venous blood by venipuncture | <1% | 194 | $7.50 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 286 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMITSTIFER, GREGORY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Upmc Pinnacle Hospitals | Harrisburg, PA | $26.92M |
| Upmc Memorial | York, PA | $6.74M |
| Upmc Hanover | Hanover, PA | $2.92M |
| Upmc Lititz | Lititz, PA | $2.49M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.